SMAP-2;CID 91885560;ANTI-SMOC2 (C-TERM) antibody produced in rabbit;SMAP2;SMOC2;SPARC-related modular calcium-binding protein 2;Anti-SMOC2 antibody produced in rabbit;MST117;MSTP117;MSTP140
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity.
性状
Solid
IC50 & Target[1][2]
PP2A
体外研究(In Vitro)
SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E-null (ApoE-/-) mice.
SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Chao Zhang, et al. Abstract 13927: Allosteric Activation of PP2A Inhibits Experimental Abdominal Aortic Aneurysm. 2018. Circulation. 2016;134:A13927.[2]. Brittany L Allen-Petersen, et al. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Jan 1;79(1):209-219.
溶解度数据
In Vitro: DMSO : 300 mg/mL (563.31 mM; Need ultrasonic)配制储备液